PUBLISHER: Grand View Research | PRODUCT CODE: 1301091
PUBLISHER: Grand View Research | PRODUCT CODE: 1301091
The global diabetes devices market size is expected to reach USD 50.3 billion by 2030, registering a CAGR of 7.5% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by factors such as the increasing incidence of diabetes, coupled with technological advancements and innovative product launches.
Rising adoption of advanced diabetes management solutions in developing regions, government policies, and rising medical tourism are some of the major factors contributing to the market growth. Furthermore, the rising government initiative to spread diabetes awareness and increasing R&D expenditure of major market players are the factors expected to ensure long-term market growth. According to the NCBI report, global health expenditure on diabetes is expected to reach USD 490 billion in 2030 from 376 billion in 2010.
Obesity, sedentary lifestyle, and fast food culture are some of the factors having a significant impact on the market growth. According to Harvard T.H. Chan School of Public Health, the U.S has the highest rates of obesity with every third person being obese and this rate is expected to reach 50% by 2030.
In addition, an increasing number of new market players are transforming the market. New market entrants focus on patient convenience with the help of artificial intelligence technology. They are leveraging technological advancements to improve diabetes care solutions like CGM devices non-invasive insulin delivery systems and digital diabetes management platforms. For Instance, In December 2017, Companion Medical Launched Inpen, its first smart insulin pen system in the U.S. It is the only FDA-approved solution that can combine insulin injector pens with a smart app.